June 22, 2020 / 7:15 PM / 18 days ago

BRIEF-Karyopharm Announces FDA Approval Of Xpovio (Selinexor) For Treatment Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

June 22 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM ANNOUNCES FDA APPROVAL OF XPOVIO® (SELINEXOR) FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

* KARYOPHARM THERAPEUTICS - MARKETING AUTHORIZATION APPLICATION FOR SELINEXOR FOR RELAPSED OR REFRACTORY DLBCL PLANNED FOR SUBMISSION TO EUROPEAN MEDICINES AGENCY IN 2021

* KARYOPHARM THERAPEUTICS INC - XPOVIO WILL BE COMMERCIALLY AVAILABLE IMMEDIATELY IN NEW INDICATION IN U.S. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below